Both IL-17 (p = 0.02) and RORγt (p = 0.01) (transcription factor) were shown to be inhibited by combined treatment with ATRA and DHA, which could be considered as a beneficial outcome, as IL-17 and RORγt were found to be upregulated in MS patients, particularly during clinical exacerbations [267]. Here, IL17A is linked to myeloid sarcoma.